Abstract:Cancer stem cells (CSCs) drive malignant tumor progression, recurrence, and metastasis with unique characteristics, including self-renewal and resistance to conventional treatments. Conventional differentiation inducers, although promising, have limited cytotoxicity and may inadvertently enhance CSC stemness. To address these challenges, ongoing efforts are dedicated to developing strategies that can effectively combine both cytotoxicity and differentiation-inducing effects. In this study, we introduce oridonin (Ori), a small molecule with dual differentiation-inducing and cytotoxicity properties capable of eliminating tumor CSCs. We isolated CSCs in B16F10 cells using the Hoechst side population method and assessed the differentiation effect of Ori. Ori's differentiation-inducing effect was further evaluated using human acute promyelocytic leukemia. The cytotoxic potential of Ori against MCF-7 and B16F10 cell lines was assessed through various methods. In vivo anti-tumor and anti-CSC efficacy of Ori was investigated using mouse melanoma and CSCs melanoma models. Safety evaluation included zebrafish embryotoxicity and mouse acute toxicity experiments. As a result, Ori effectively dismantles tumorspheres, inhibits proliferation, and reduces the expression of CSC-specific markers. It induces significant differentiation, especially in the case of NB4. Additionally, Ori upregulates TP53 expression, mitigates the hypoxic tumor microenvironment, suppresses stemness, and inhibits PD-L1 expression, prompting a robust anti-cancer immune response. Ori demonstrates pronounced cytotoxicity, inducing notable pro-apoptotic effects on B16F10 and MCF-7 cells, with specific triggering of mitochondrial apoptosis. Importantly, Ori maintains a commendable biosafety record. The dual-action prowess of Ori not only induces the differentiation of CSCs but also dispatches differentiated and residual tumor cells, effectively thwarting the relentless march of tumor progression.

Oridonin Nanosuspension Enhances Anti-Tumor Efficacy in SMMC-7721 Cells and H22 Tumor Bearing Mice

In Vitro and in Vivo Antitumor Activity of Oridonin Nanosuspension

Oridonin Inhibits Bxpc-3 Cell Growth Through Cell Apoptosis

Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway

Oridonin Nanosuspension Was More Effective Than Free Oridonin on G2/M Cell Cycle Arrest and Apoptosis in the Human Pancreatic Cancer PANC-1 Cell Line.

Growth Inhibition and Induction of Apoptosis in Mcf-7 Breast Cancer Cells by Oridonin Nanosuspension

Preparation of Oridonin Nanocrystals and Study of Their Endocytosis and Transcytosis Behaviours on MDCK Polarized Epithelial Cells.

Effects of Oridonin on Proliferation of HT29 Human Colon Carcinoma Cell Lines Both in Vitro and in Vivo in Mice.

Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc

Preparation of nano-crystalline of oridonin and its effect on cell proliferation and apoptosis of colorectal cancer cells in vitro

Oridonin-loaded poly(ε-caprolactone)–poly(ethylene oxide)–poly(ε-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway

Research and Development Progression of Oridonin for Hematological Malignancies Therapy

In Vivo Studies On The Oridonin-Loaded Nanostructured Lipid Carriers

Galactosylated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Oridonin

Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects

Figure S6 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma <i>in Vitro</i> and Patient-Derived Xenografts <i>in Vivo</i>

Oridonin Exerts Anticancer Effect on Osteosarcoma by Activating PPAR-γ and Inhibiting Nrf2 Pathway.

Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells

Oridonin, a small molecule inhibitor of cancer stem cell with potent cytotoxicity and differentiation potential

Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier